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Abstract: Neglected diseases represent a major health problem. It is estimated that one third 
of the world population is infected with tuberculosis (TB). Besides TB, Chagas disease, 
affects approximately 20 million people. Quinoxalines display great activities against TB 
and Chagas. Forty new quinoxaline 1,4-di-N-oxide derivatives have been prepared and 
tested against M. tuberculosis and T. cruzi. Carboxylic acid quinoxaline 1,4-di-N-oxides 
(CAQDOs) 5 and 17 showed MIC values on the same order as the reference antituberculosis 
drug, rifampicin. Meanwhile, CAQDOs 12 and 22 presented IC50 values in the same order 
as the anti-chagasic drug, nifurtimox. 
Keywords: quinoxaline; neglected diseases; Mycobacterium tuberculosis; Trypanosoma 
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Introduction 
Mycobacterium tuberculosis (M. tuberculosis), and to a lesser extent M. bovis and M. africanum, 
can cause a chronic and fatal condition in humans known as tuberculosis (TB). Until about 50 years 
ago, this disease was considered virtually incurable. The discovery of several active anti-TB agents 
heralded a new age of anti-TB chemotherapy. Therefore, TB was considered to be a curable disease. 
Unfortunately, in only a few years, it became apparent that the use of these drugs as single agents led 
to rapid drug resistance and treatment failures among a substantial number of patients. It was quickly 
realized, however, that the development of resistance could be forestalled or prevented through 
treatment with several active agents in a combination regimen. Of particular concern is the 
development of multi-drug-resistant forms of the disease (MDR-TB), defined as forms resistant to two 
or more of the front line anti-TB agents. These forms of the disease are most often fatal and are 
difficult and expensive to treat. It is estimated that one third of the world’s population is infected with 
TB, with about eight million new cases annually. Of these cases, 3.1 million die annually, more deaths 
than those caused by any other single infectious disease. TB is the leading killer of youths, women, 
and AIDS patients in the world [1,2]. HIV-infected patients have an elevated risk of tuberculosis, and 
such active infectious process may enhance HIV replication and increase the risk of death. It has been 
estimated that up to 50 million people are infected with drug-resistant forms of TB. Due to the fact that 
the current frontline therapy for TB consists of administering three different drugs (the antibiotic 
rifampicin, RIF, and the azaheterocycles isoniazid and pyrazinamide, Isnz and Pyzd, Scheme 1) over 
an extended period of time as well as the problems that arise due to MDR-TB, it is necessary to 
develop new, potent, fast-acting anti-tuberculosis drugs with low-toxicity profiles for treating drug 
resistant forms of the disease that can be given in conjunction with drugs used to treat HIV  
infections [3,4]. 
Besides TB, the parasitic diseases represent a major health problem in Third World countries. More 
specifically, Chagas disease, or American trypanosomiasis, caused by the protozoan Trypanosoma 
cruzi (T. cruzi), is the largest parasitic disease burden in the American continents. It affects 
approximately 20 million people from the southern United States to southern Chile. Even though the 
enforcement of public health programs towards vector elimination in some Latin American countries 
has decreased the incidence of new infections, the disease is still endemic in large areas. Every year, 
21,000 people die from this parasitosis and over 200, 000 new cases arise [5]. Currently, there are only 
two clinically used drugs, nifurtimox (Nfx, Scheme 1) and benznidazole. Both are nitroheterocyclic 
compounds that possess important toxic effects and relative clinical efficacy; therefore, the 
pharmacotherapy of Chagas disease is very deficient and there is an urgent need for the development 
of safe and effective drugs [6]. 
Quinoxalines, including their fused-ring derivatives, display diverse pharmacological activities and 
more specifically, their 1,4-di-N-oxides have demonstrated excellent activities as antiviral, anticancer, 
antibacterial, and antiparasitic agents [7]. In this sense, our group published several studies in which 
the synthesis and biological evaluation of a large amount of quinoxaline 1,4-di-N-oxides (QDO) have 
been described. We have focused our recent efforts on the development of QDO with activities against 
the agents responsible of some of the well-known neglected diseases. We have found QDO with good 
in vitro selectivity against M. tuberculosis (i.e. parent compounds 1 and 2, Scheme 1) [8-16] and 
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against T. cruzi (i.e. parent compound 3, Scheme 1) [17,18], and in both cases, recognizing some 
structural requirements for optimal activity [12-20]. 
Galactofuranose is an essential component of the mycobacterial cell wall, not found in man; UDP-
galactofuranose is biosynthesized from UDP-galactopyranose using the enzyme UDP-galactose 
mutase (Glf). In 2004, Tangallapally et al. discovered that nitrofuryl derivatives have the requirements 
for optimum inhibition of Glf activity (i.e. compound 4, Scheme 1) [4]. In addition, the nitrofuryl 
moiety is present in a large number of anti-T. cruzi agents acting via a nitroreduction process, 
generating  redox cycling at different levels [21]. Based on these structural features, we have designed 
a new series of quinoxaline 1,4-di-N-oxide derivatives containing a nitrofuryl side chain as potential 
anti-neglected diseases agents. More specifically, we have designed new hybrid QDO with potential 
anti-tubercular activity combining some previous structural features, amide and cyano QDO 
substituents, and the heteroaryl retro-amide moieties. In order to determine the action of the 5-
nitrofuryl moiety, we synthesized another analogue series by substituting this group by a 5-nitrothienyl 
one, and in order to determine the influence of the nitro group, another two series were designed, furyl 
and thienyl side chains (Table 1). Moreover, the same designed compounds could also act as hybrid 
potential anti-T. cruzi agents because they are QDO that have maintained the 3-cyano and 2-NH, as 
retro-amide moieties, with the extra-heteroaryl substituents (5-nitrofuryl, 5-nitrothienyl, furyl, and 
thienyl groups). 
 
Scheme 1. Design of new QDOs as potential drugs against neglected diseases. 
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Results and Discussion 
We have prepared forty new heterocyclic-2-carboxylic acid (3-cyano-1,4-di-N-oxidequinoxalin-2-
yl)-amide derivatives (CAQDOs). The benzofuroxane starting compounds,  (BFX, I, Scheme 2), have 
been prepared using previously described methods [11,22]. The 3-amine-1,4-di-N-oxide quinoxaline-
2-carbonitrile derivatives (cyanoamines, II) were obtained by the Beirut reaction from the 
corresponding BFX, with malononitrile using N,N-dimethylformamide (DMF) as solvent and 
triethylamine as catalyst [23]. Finally, the new CAQDOs were synthesized using two different routes, I 
and II (Scheme 2) [4, 24]. Furyl and thienyl derivatives 5-24 were obtained by reaction between 
intermediates II with an excess of the corresponding, commercially available, heteroaryl-2-carbonyl 
chloride. Another synthetic route was optimized for the synthesis of 5-nitrofuryl and 5-nitrothienyl 
derivatives 25-44. In these cases, the reaction was carried out by condensation between intermediates 
II and the corresponding carboxylic acid, 5-nitrofuryl and 5-nitrothienyl carboxylic acid, activated in 
the presence of EDCI and DMAP and DMF as solvent.  
 
Scheme 2. Synthetic route to heterocyclic-2-carboxylic acid (3-cyano-1,4-di-N-
oxidequinoxalin-2-yl)-amide derivatives 5-44. 
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In order to carry out an in depth QSAR study, CAQDO were un-substituted or substituted in 
positions 6 and 7 by chloro- or fluoro- or trifluoromethyl-moiety as electron-withdrawing groups and 
by methyl- or methoxy-moiety as electron-releasing groups. When the new CAQDOs were prepared 
from monosubstituted-BFX, a mixture of positional isomers was obtained. Generally, it could be 
observed that the 6-substituted isomer prevailed over the 7-substituted isomer [25]. When the 
substituent was a methoxy moiety, a regio-specific reaction was achieved because only 6-isomer was 
isolated. In the other case, when 5-trifluoromethyl-BFX was reacted, the two CAQDO-isomers were 
obtained in similar proportions and separated by chromatography. 
The new developed CAQDOs were subjected to the following set of tests: i) determination of the 
MICs, in μg/mL, against M. tuberculosis H37Rv strain and, ii) determination of the percentage of 
growth inhibition, at 25 μM, and IC50 values, in μM, against T. cruzi Tulahuen 2 strain (Table 1). 
With regard to the anti-M. tuberculosis evaluations, the CAQDO 5 and 17 were identified as the 
most active derivatives against H37Rv strain, with MIC values on the same order as the reference 
compound, RIF (Table 1). Some structure-activity relationships could be established; in general, 
thienyl-derivatives are more active than furyl derivatives (cf. the anti-M. tuberculosis activities of 16 
and 6, 19 and 9, 23 and 13, 24 and 14, 38 and 28, 43 and 33, or 44 and 34), whereas the effect of the 5-
nitro substitution is clear only for the thienyl series (cf. the anti-M. tuberculosis activities of 35 and 15, 
38 and 18, 43 and 23, or 44 and 24), with the 5-nitrothienyl-derivatives being more active than the un-
substituted ones. For this biological activity we were unable to find relationships between this and the 
electronic characteristics of benzo-substituent on the quinoxaline heterocycle. However, it could be 
pointed out, bearing in mind derivatives 29-32, that the mono-halogen substitution produce 
compounds more actives than the di-halogen substituted ones furthermore chlorine-substitution is 
better for the activity than fluorine-substitution. Considering the couple of derivatives 13 and 14, 23 
and 24, 33 and 34, and 43 and 44 the 7-trifluoromethyl-substitution produces more active compounds. 
With regard to the anti-T. cruzi evaluations, the difluoro substituted CAQDOs 12 and 22 were 
identified as the most active derivatives against the Tulahuen 2 strain, with IC50 values on the same 
order as the reference compound, Nfx. Moreover, compound 22 was found more active than the parent 
compound 3 (Scheme 1, Table 1). Similar to M. tuberculosis, the thienyl-derivatives are more active 
than furyl derivatives (compare anti-T. cruzi activities of 22 and 12), unlike in the case of M. 
tuberculosis, in which the influence of the 5-nitro substitution is clear, with the 5-nitro-substituted 
derivatives being less active than the un-substituted derivatives (compare anti-T. cruzi activities of 42 
and 22). In T. cruzi findings, some relationships between the electronic characteristics of benzo-
substituent, on the quinoxaline heterocycle, and the activity could be established; for example, when 
the electron-withdrawing property increases, the activity increases (compare activity of compound 10 
with 8 or 7, 12 and 10, 22 and 21, or 40 and 39). The hybridization process, pharmacophore 
quinoxaline dioxide plus pharmacophore nitrofurane, does not produce active compounds. 
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Table 1. Biological characterization of the forty new quinoxaline 1,4-di-N-oxides. 
N
+
N
+
N
X
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N
H
O
O
R6
R7
W
 
Cpd. X W R7 R6 MICa(g/mL) %GIb 
5 O H H H 0.977 3.1 
6 O H H CH3 8.843 11.6 
7 O H CH3 CH3 NTc 13.1 
8 O H H OCH3 NT 9.5 
9 O H H Cl 15.361 NT 
10 O H Cl Cl NT 31.6 
11 O H H F NT 19.8 
12 O H F F 4.700 53.1 (IC50=19.2) 
13 O H CF3 H 17.903 NT 
14 O H H CF3 24.220 NT 
15 S H H H 5.381 19.0 
16 S H H CH3 2.082 16.4 
17 S H CH3 CH3 1.190 13.5 
18 S H H OCH3 48.909 15.1 
19 S H H Cl 2.470 NT 
20 S H Cl Cl 13.612 NT 
21 S H H F 1.474 27.5 
22 S H F F NT 92.4 (IC50=10.8) 
23 S H CF3 H 4.576 NT 
24 S H H CF3 9.177 NT 
25 O NO2 H H NT 0.7 
26 O NO2 H CH3 NT 0.0 
27 O NO2 CH3 CH3 NT 0.0 
28 O NO2 H OCH3 14.493 NT 
29 O NO2 H Cl 5.811 NT 
30 O NO2 Cl Cl 13.573 NT 
31 O NO2 H F 21.675 NT 
32 O NO2 F F 22.161 NT 
33 O NO2 CF3 H 12.816 NT 
34 O NO2 H CF3 14.408 NT 
35 S NO2 H H 2.875 0.0 
36 S NO2 H CH3 NT 11.4 
37 S NO2 CH3 CH3 NT 36.4 
38 S NO2 H OCH3 9.538 NT 
39 S NO2 H Cl NT 15.0 
40 S NO2 Cl Cl NT 29.8 
41 S NO2 H F NT 2.5 
42 S NO2 F F NT 9.2 
43 S NO2 CF3 H 1.695 NT 
44 S NO2 H CF3 6.001 NT 
3 - - - - - 63.0d 
RIF - - - - 0.125 - 
Nfx - - - - - 100.0 (7.7) 
a Minimum inhibitory concentration against M. tuberculosis H37Rv. b Percentage of growth 
inhibition at 25 μM doses in T. cruzi Tulahuen 2 strain. c NT: Not tested. d From  
reference [17]. 
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Experimental  
 
General 
 
All of the synthesized compounds were chemically characterized by thin layer chromatography 
(TLC), infrared (IR), proton nuclear magnetic resonance (1H-NMR), mass spectra (MS) and elemental 
microanalyses (CHN). Alugram SIL G/UV254 (Layer: 0.2 mm) (Macherey-Nagel GmbH & Co. KG., 
Düren, Germany) was used for TLC and Silica gel 60 (0.040-0.063 mm, Merck) was used for Flash 
Column Chromatography. The 1H-NMR spectra were recorded on a Bruker 400 Ultrashield instrument 
(400 MHz), using TMS as internal standard and with DMSO-d6 as solvent; the chemical shifts are 
reported in ppm (δ) and coupling constants (J) values are given in Hertz (Hz). Signal multiplicities are 
represented by: s (singlet), bs (broad singlet), d (doublet), t (triplet), q (quadruplet), dd (double 
doublet) and m (multiplet). The IR spectra were recorded on a Nicolet Nexus FTIR (Thermo, Madison, 
USA) in KBr pellets. Elemental microanalyses were obtained on a CHN-900 Elemental Analyzer 
(Leco, Tres Cantos, Spain) from vacuum-dried samples. The analytical results for C, H and N, were 
within ± 0.5 of the theoretical values. Chemicals were purchased from Panreac Química S.A. 
(Barcelona, Spain), Sigma-Aldrich Química, S.A. (Alcobendas, Spain), Acros Organics (Janssen 
Pharmaceutical, Geel, Belgium) and Lancaster (Bischheim-Strasbourg, France). 
General procedure for the synthesis of cyanoamines II 
Malononitrile (18.0 mmol) was added to a solution of the appropriate benzofuroxane (I, 15.0 mmol) 
in DMF (10 mL). The mixture was allowed to stand at 0 °C. Triethylamine was added dropwise (1.5 
mL), and the reaction mixture was stirred at room temperature in darkness for 1-3 days. The 
precipitate was filtered off and washed by adding diethyl ether affording the target compound. The 
obtained red solid was used in the next step without further purification. 
General procedure for the synthesis of furan-2-carboxylic acid (3-cyano-1,4-di-N-oxide-quinoxalin-2-
yl)-amide derivatives and thiophene-2-carboxylic acid (3-cyano-1,4-N-oxide-quinoxalin-2-yl)-amide 
derivatives 5-24 
The corresponding 3-amino-1,4-di-N-oxide-quinoxaline-2-carbonitrile II (2 mmol) is dissolved in 
acetonitrile (100 mL) and triethylamine (0.4 mL) was added at room temperature under stirring and 
anhydrous conditions. After cooling the reaction mixture with an ice bath, 2-furoyl chloride or 2-
tiophenecarbonyl chloride (2.2 mmol) are added. The reaction mixture is stirred for 9 h at room 
temperature. The obtained solid is filtered and EtOAc (400 mL) added to the filtrate. The organic 
phase is extracted, first with HCl 10% and then with water. The organic phase is dried with anhydrous 
Na2SO4 and filtered. The solvent is removed in vacuo and the resulting residue is precipitated with 
diethyl ether, and then filtered in order to obtain a yellow-orange solid. 
Furan-2-carboxylic acid (3-cyano-1,4-di-N-oxidequinoxalin-2-yl)amide (5). Yield 64.4 %; 1H-NMR  
ppm: 11.43 (bs, 1H, NH); 8.53-8.48 (m, 2H, H8+H5); 8.13-8.01 (m, 3H, H6+H7+H5’); 7.60 (d, 1H, H3´, 
J3´-4´ = 3.5 Hz); 6.81 (dd, 1H, H4´, J4´-5 ´= 1.7 Hz); IR  cm-1: 3,237 (m, NH); 2,236 (w, C≡N); 1,686 (s, 
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C=O); 1,335 (s, N+O-); Anal. Calc.  for C14H8N4O4: C: 56.76%; H: 2.72%; N: 18.91%. Found: C: 
56.73%; H: 3.13%; N: 18.93%. 
Furan-2-carboxylic acid (3-cyano-1,4-di-N-oxide-6-methylquinoxalin-2-yl)amide (6). Yield 63.0 %; 
1H-NMR  ppm: 11.37 (bs, 1H, NH); 8.42 (d, 1H, H8, J8-7 = 8.8 Hz); 8.31 (d, 1H, H5, J5-7 = 1.3 Hz); 
8.10 (d, 1H, H5´, J5´-4´ = 1.7 Hz); 7.95 (dd, 1H, H7); 7.69 (d, 1H, H3´, J3´-4´ = 3.6 Hz), 6.81 (dd, 1H, H4´), 
2.61 (s, 3H, CH3); IR  cm-1: 3,114 (m, NH); 2,238 (w, C≡N); 1,692 (s, C=O); 1,325 (s, N+O-); Anal. 
Calc.  for C15H10N4O4: C: 58.07%; H: 3.25%; N: 18.06%. Found: C: 57.95%; H: 3.27%; N: 18.43%. 
Furan-2-carboxylic acid (3-cyano-1,4-di-N-oxide-6,7-dimethylquinoxalin-2-yl)amide (7). Yield 75.3 
%; 1H-NMR  ppm: 11.33 (bs, 1H, NH); 8.31 (s, 1H, H8); 8.28 (s, 1H, H5); 8.09 (d, 1H, H5´, J5´-4´ = 1.5 
Hz); 7.68 (d, 1H, H3´, J3´-4´ = 3.5 Hz); 6.80 (dd, 1H; H4´); 2.54-2.52 (m, 6H, 2xCH3); IR  cm-1: 3,285 
(w, NH); 2,236 (w, C≡N); 1,709 (s, C=O); 1,324 (s, N+O-); Anal. Calc. for C16H12N4O4: C: 59.26%; H: 
3.73%; N: 17.28%. Found: C: 59.33%; H: 3.77%; N: 17.30%. 
Furan-2-carboxylic acid (3-cyano-1,4-di-N-oxide-6-methoxyquinoxalin-2-yl)amide (8). Yield 50.5 %; 
1H-NMR  ppm: 11.31 (bs, 1H, NH); 8.44 (d, 1H, H8, J8-7 = 9.4 Hz); 8.09 (s, 1H, H5); 7.78 (d, 1H, H5´, 
J5´-4´ = 2.4 Hz); 7.73 (d, 1H, H7); 7.67 (d, 1H, H3´, J3´-4’ = 3.10 Hz), 6.80 (dd, 1H, H4’); 4.03 (s, 3H, 
OCH3); IR  cm-1: 3,298 (m, NH); 2,241 (w, C≡N); 1,698 (s, C=O); 1,321 (s, N+O-); Anal. Calc. for 
C15H10N4O5: C: 55.22%; H: 3.09%; N: 17.17%. Found: C: 54.87%; H: 3.09%; N: 16.79%. 
Furan-2-carboxylic acid (3-cyano-6-chloro-1,4-di-N-oxidequinoxalin-2-yl)amide (9). Yield 6.1 %; 1H-
NMR  ppm: 11.47 (bs, 1H, NH); 8.51-8.50 (m, 2H, H8+H5); 8.14 (dd, 1H, H7, J7-8 = 9.1 Hz, J7-5 = 2.3 
Hz); 8.10 (d, 1H, H5´, J5´-4 ´= 1.7 Hz); 7.70 (d, 1H, H3´, J3´-4´ = 3.6 Hz); 6.81 (dd, 1H, H4´, J4´-3’ = 3.6 Hz, 
J4´-5’ = 1.7 Hz); IR  cm-1: 3,288 (m, NH); 2,241 (w, C≡N); 1,692 (s, C=O); 1,320 (s, N+O-); Anal Calc. 
for C14H7ClN4O4: C: 50.58%; H: 2.13%; N: 16.94%. Found: 50.91%; H: 2.23%; N: 16.69%. 
Furan-2-carboxylic acid (3-cyano-6,7-dichloro-1,4-di-N-oxidequinoxalin-2-yl)amide (10). Yield 51.0 
%; 1H-NMR  ppm: 11.56 (bs, 1H, NH); 8.72 (s, 2H, H8+H5); 8.11 (dd, 1H, H5´, J5´-4´ = 1.7 Hz, J5´-3´ = 
0.7 Hz); 7.72 (d, 1H, H3´, J3´-4´ = 3.6 Hz); 6.81 (dd, 1H, H4); IR  cm-1: 3,275 (m, NH); 2,232 (w, 
C≡N); 1,702 (s, C=O); 1,336 (s, N+O-); Anal. Calc. for C14H6Cl2N4O4: C: 45.04%; H: 1.61%; N: 
15.01%. Found: C: 45.34%; H: 1.75%; N: 15.18%. 
Furan-2-carboxylic acid (3-cyano-1,4-di-N-oxide-6-fluoroquinoxalin-2-yl)amide (11). Yield 57.8 %; 
1H-NMR  ppm: 11.44 (bs, 1H, NH); 8.59 (dd, 1H, H8, J8-F = 5.0 Hz); 8.30 (dd, 1H, H5, J5-F = 8.6 Hz, 
J5-7 = 2.7 Hz); 8.10 (d, 1H, H5´, J5´-4´ = 1.5 Hz); 8.03 (ddd, 1H, H7, J7-F  = 7.9 Hz); 7.70 (d, 1H, H3´, J3´-
4´= 3.6 Hz); 6.81 (dd, 1H, H4’); IR  cm-1: 3,263 (m, NH); 2,239 (w, C≡N); 1,681 (s, C=O); 1,328 (s, 
N+O-); 1,242 and 1,171 (m, Ar-F); Anal. Calc. for C14H7FN4O4: C: 53.51%; H: 2.25%; N: 17.83%. 
Found: C: 53.06%; H: 2.27%; N: 17.86%. 
Furan-2-carboxylic acid (3-cyano-6,7-difluoro-1,4-di-N-oxidequinoxalin-2-yl)amide (12). Yield 66.1 
%; 1H-NMR  ppm: 11.50 (bs, 1H, NH); 8.65-8.58 (m, 2H, H8+H5); 8.10 (dd, 1H, H5´, J5´-4´= 1.6 Hz, 
J5´-3´ = 0.6 Hz); 7.71 (dd, 1H, H3´, J3´-4´ = 3.7 Hz); 6.81 (dd, 1H, H4´); IR  cm-1: 3,215 (m, NH); 2,236 
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(w, C≡N); 1,689 (s, C=O); 1,340 (s, N+O-); 1,270 and 1,181 (m, Ar-F); Anal. Calc. for C14H6F2N4O4: 
C: 50.61%; H:1.82%; N: 16.86%. Found: C: 50.37%; H: 1.98%; N: 16.67%. 
Furan-2-carboxylic acid (3-cyano-1,4-di-N-oxide-7-trifluoromethylquinoxalin-2-yl)amide (13). Yield 
78.1 %; 1H-NMR  ppm: 12.06 (bs, 1H, NH); 8.69 (s, 1H, H8); 8.64 (d, 1H, H5, J5-6 = 9.0 Hz); 8.37 (d, 
1H, H6); 8.07 (d, 1H, H5´, J5´-4´ = 1.7 Hz); 7.66 (d, 1H, H3´); 6.79 (d, 1H, H4´, J3´-4´ = 3.5 Hz); IR  cm-1: 
3,279 (m, NH); 2,244 (w, C≡N); 1,688 (s, C=O); 1,325 (s, N+O-); 1,137 (s, CF3); Anal. Calc. for 
C15H7F3N4O4: C: 49.46%; H: 1.96%; N: 15.38%. Found: C: 49.18%; H: 2.02%; N: 15.31%. 
Furan-2-carboxylic acid (3-cyano-1,4-di-N-oxide-6-trifluoromethylquinoxalin-2-yl)amide (14). Yield 
31.1 %; 1H-NMR  ppm: 12.06 (bs, 1H, NH); 8.72 (d, 1H, H5, J5-7= 1.7 Hz); 8.66 (d, 1H, H8, J8-7= 9.0 
Hz); 8.30 (dd, 1H, H7, J7-8 = 9.0 Hz, J7-5= 1.7 Hz); 8.09 (dd, 1H, H5´, J5´-4´ = 1.7 Hz, J5´-3´= 0.7 Hz); 
7.69 (dd, 1H, H3´, J3´-4´= 3.6 Hz); 6.80 (dd, 1H, H4´); IR  cm-1: 3,263 (m, NH); 2,232 (w, C≡N); 1,701 
(s, C=O); 1,341 (s, N+O-); 1,132 (s, CF3); Anal. Calc. for C15H7F3N4O4: C: 49.46%; H: 1.96%; N: 
15.38%. Found: C: 49.59%; H: 1.89%; N: 15.09%. 
Thiophene-2-carboxylic acid (3-cyano-1,4-di-N-oxidequinoxalin-2-yl)amide (15). Yield 33.3 %; 1H- 
NMR  ppm: 11.65 (bs, 1H, NH); 8.54 (dd, 1H, H8, J8-7 = 8.6 Hz, J8-6 = 0.7 Hz); 8.50 (dd, 1H, H5, J5-6 
= 8.6 Hz, J5-7 = 0.8 Hz); 8.30 (dd, 1H, H5’, J5’-4´= 3.7 Hz, J5´-3’ = 0.9 Hz); 8.12 (td, 1H, J6-7 = 7.1 Hz, 
H6); 8.10-8.00 (m, 2H, H7, H3’); 7.32 (dd, 1H, H4´, J4´-3’ = 4.9 Hz, J4’-5’ = 3.9 Hz); IR  cm-1: 3,231 (m, 
NH); 2,232 (w, C≡N); 1,681 (s, C=O); 1,326 (s, N+O-); Anal. Calc. for C14H8N4O3S: C: 53.85%; H: 
2.56%; N: 17.95%. Found: C: 53.88%; H: 2.82%; N: 18.35%.  
 
Thiophene-2-carboxylic acid (3-cyano-1,4-di-N-oxide-6-methylquinoxalin-2-yl)amide (16). Yield 1.2 
%; 1H-NMR  ppm: 11.62 (bs, 1H, NH); 8.39 (d, H8, 1H, J8-7 = 8.8 Hz); 8.35 (s, 1H, H5); 8.30 (m, 1H, 
H5’); 8.05 (d, 1H, H3’, J3’-4 ’= 4.9 Hz); 7.88 (d, 1H, H7); 7.33-7.31 (m, 1H, H4’); 2.66 (s, 3H, CH3); IR  
cm-1: 3,276 (w, NH); 2,225 (w, C≡N); 1,664 (s, C=O); 1,329 (s, N+O-); Anal. Calc. for C15H10N4O3S: 
C: 55.22%; H: 3.07%; N: 17.18%. Found: C: 55.01%; H: 3.17%; N: 17.39%. 
Thiophene-2-carboxylic acid (3-cyano-6,7-dimethyl-1,4-di-N-oxidequinoxalin-2-yl)amide (17). Yield 
1.4 %; 1H-NMR  ppm: 11.59 (bs, 1H, NH); 8.32 (s, 1H, H5’); 8.28 (s, 2H, H8+H5); 8.03 (s, 1H, H3’); 
7.31 (s, 1H, H4’); 2.6-2.4 (m, 6H, 2xCH3); IR  cm-1: 3,206 (m, NH); 2,225 (w, C≡N); 1,667 (s, C=O); 
1,327 (s, N+O-); Anal. Calc. for C16H12N4O3S: C: 56.47%; H: 3.53%; N: 16.47%. Found: C: 56.72%; 
H: 3.64%; N: 16.72%. 
Thiophene-2-carboxylic acid (3-cyano-1,4-di-N-oxide-6-methoxyquinoxalin-2-yl)amide (18). Yield 
41.1 %; 1H-NMR  ppm: 11.53 (bs, 1H, NH); 8.46 (d, 1H, H8, J8-7 = 9.4 Hz); 8.28 (dd, 1H, H5’, J5’-4’ = 
3.8 Hz, J5’-3’ = 0.9 Hz); 8.05 (dd, 1H, H3’, J3’-4’= 3.8 Hz); 7.79 (d, 1H, H5, J5-7 = 2.7 Hz); 7.73 (dd, 1H, 
H7); 7.32 (dd, 1H, H4’); 4.03 (s, 3H, OCH3); IR  cm-1: 3,276 (m, NH); 2,232 (w, C≡N); 1,673 (s, 
C=O); 1,320 (s, N+O-); Anal. Calc. for C15H10N4O4S: C: 52.63%; H: 2.93%; N: 16.37%. Found: C: 
52.49%; H: 3.06%; N: 16.35%. 
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Thiophene-2-carboxylic acid (6-chloro-3-cyano-1,4-di-N-oxidequinoxalin-2-yl)amide (19). Yield 33.2 
%; 1H-NMR  ppm: 11.66 (bs, 1H, NH); 8.54-8.48 (m, 2H, H8+H5); 8.30 (dd, 1H, H5’, J5’-4’=3.8 Hz, 
J5’-3’=0.8 Hz); 8.15 (dd, 1H, H7, J7-8 = 9.30 Hz, J7-5 = 2.2 Hz,); 8.06 (dd, 1H, H3’, J3’-4’ = 5.0 Hz); 7.32 
(t, 1H, H4’); IR  cm-1: 3,295 (m, NH); 2,251 (w, C≡N); 1,671 (s, C=O); 1,323 (s, N+O-); Anal. Calc. 
for C14H7ClN4O3S: C: 48.48%; H: 2.02%; N: 16.16%. Found: C: 48.58%; H: 2.16%; N: 16.15%. 
Thiophene-2-carboxylic acid (3-cyano-6,7-dichloro-1,4-di-N-oxidequinoxalin-2-yl)amide (20). Yield 
19.4 %; 1H-NMR ppm: 8.66 (s, 1H, H8); 8.64 (s, 1H, H5); 8.13 (s, 1H, H5’); 7.96 (d, 1H, H3’, J3’-4’ = 
4.7 Hz) 7.32 (dd, 1H, H4’, J4’-5’  = 3.9 Hz,); IR KBr (trans): 3,263 (m, NH); 2,238 (w, C≡N); 1,668 (s, 
C=O); 1,335 (s, N+O-); Anal. Calc. for C14H6Cl2N4O3S: C: 44.09%; H: 1.57%; N: 14.70%. Found: C: 
43.83%; H: 1.67%; N: 14.70%. 
Thiophene-2-carboxylic acid (3-cyano-1,4-di-N-oxide-6-fluoroquinoxalin-2-yl)amide (21). Yield 46.0 
%; 1H-NMR  ppm: 11.63 (bs, 1H, NH); 8.60 (dd, 1H, H8, J8-7 = 9.5 Hz, J8-F = 4.9 Hz,); 8.31-8.27 (m, 
2H, H5+H5´); 8.06-8.01 (m, 2H, H7+H3´); 7.32 (t, 1H, H4’); IR  cm-1: 3,263 (m, NH); 2,226 (w, C≡N); 
1,665 (s, C=O); 1,327 (s, N+O-); Anal. Calc. for C14H7FN4O3S: C: 50.91%; H: 2.12%; N: 16.97%. 
Found: C: 51.18%; H: 2.24%; N: 17.06%. 
Thiophene-2-carboxylic acid (3-cyano-6,7-difluoro-1,4-di-N-oxidequinoxalin-2-yl)amide (22). Yield 
69.1 %; 1H-NMR  ppm: 11.74 (bs, 1H, NH); 8.70-8.50 (m, 2H, H8+H5); 8.25-8.35 (m, 1H, H5’); 8.07 
(d, 1H, H3’, J3´-4´  = 4.9 Hz); 7.34-7.31(m, 1H, H4’); IR  cm-1: 3,238 (m, NH); 2,238 (w, C≡N); 1,673 
(s, C=O); 1,341 (s, N+O-); Anal. Calc. for C14H6F2N4O3S: C: 48.27%; H: 1.72%; N: 16.01%. Found: 
C: 48.47%; H: 1.80%; N: 16.18%. 
Thiophene-2-carboxylic acid (3-cyano-7-trifluoromethyl-1,4-di-N-oxidequinoxalin-2-yl)amide (23). 
Yield 11.7 %; 1H-NMR ppm: 11.85 (bs, 1H, NH); 8.75 (d, 1H, H8, J8-6 = 0.75 Hz); 8.65 (d, 1H, H5, 
J5-6 = 9.0 Hz); 8.39 (dd, 1H, H6, J6-5 = 9.1 Hz, J6-8 = 1.8 Hz); 8.27 (dd, 1H, H5’, J5’-4’ = 3.8 Hz, J5’-3’ = 
1.1 Hz); 8.05 (dd, 1H, H3’, J3’-4’ = 5.0 Hz); 7.31 (dd, 1H, H4’); IR KBr (trans): 3,263 (w, NH); 2,238 (w, 
C≡N); 1,668 (s, C=O); 1,335 (s, N+O-); Anal. Calc. for C15H7F3N4O3S: C: 47.37%; H: 1.84%; N: 
14.74%. Found: C: 47.67%; H: 1.77%; N: 14.80%. 
Thiophene-2-carboxylic acid (3-cyano-6-trifluoromethyl-1,4-di-N-oxidequinoxalin-2-yl)amide (24). 
Yield 12.8 %; 1H-NMR ppm: 11.83 (bs, 1H, NH); 8.74 (s, 1H, H5); 8.68 (d, 1H, H8, J8-7 = 9.24 Hz); 
8.35-8.28 (m, 2H, H7, H5’); 8.06 (dd, 1H, H3’, J3’-4’ = 5.0 Hz, J3’-5’ = 1.0 Hz); 7.33-7.31 (m, 1H, H4’); IR 
KBr (trans): 3,270 (w, NH); 2,226 (w, C≡N); 1,679 (s, C=O); 1,339 (s, N+O-); Anal. Calc. for 
C15H7F3N4O3S: C: 47.37%; H: 1.84%; N: 14.74%. Found: C: 47.11%; H: 1.74%; N: 14.64%. 
General procedure for the synthesis of 5-nitrofuran-2-carboxylic acid (3-cyano-1,4-di-N-oxide-
quinoxalin-2-yl)amide derivatives and 5-nitrothiophene-2-carboxylic acid (3-cyano-1,4-N-oxide-
quinoxalin-2-yl)amide derivatives 25-44 
To a solution of the corresponding 3-amino-1,4-di-N-oxide-quinoxaline-2-carbonitrile II (2 mmol) 
in DMF (5 mL) are added 5-nitrothiophene-2-carboxylic acid or 5-nitrofuran-2-carboxylic acid (3 
mmol). The reaction mixture is then gently stirred at room temperature under anhydrous conditions. 
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Continuing with the synthesis, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
(EDCI, 6 mmol) are added, and the color changes to dark-red. When the dissolution is completed, 4-
dimethyl-aminopyridine (DMAP, 6 or 7 mmol) are added. The reaction mixture is stirred between 17 
h-72 h. After that, EtOAc (200 mL) is added and the organic phase is extracted, first with 10% HCl 
and then with saturated NaHCO3. The basic phase is treated with HCl 37% until pH 2, usually shown 
by the color changing to yellow. This phase is extracted with dichloromethane (3 × 75 mL), dried with 
anhydrous Na2SO4 and filtered. The solvent is removed in vacuo. The resulting residue is precipitated 
with diethyl ether and filtered in order to obtain a yellow-orange solid. Sometimes, when DMAP is 
added, the compound precipitates due to its acidity. In those cases, HCl (300 mL) is added and the 
mixture is stirred gently. The 3-amino-1,4-di-N-oxide-quinoxaline-2-carbonitrile derivatives are 
dissolved, and the precipitated compound is filtered. The compound is first washed with 10% HCl  and 
then with diethyl ether. 
5-Nitrofuran-2-carboxylic acid (3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)-amide (25). Yield 27.8 %; 
1H-NMR  ppm: 8.52-8.48 (m, 2H, H8+H5); 8.14-8.10 (m, 1H, H7); 8.06-8.02 (m,1H, H6); 7.91 (d, 1H, 
H4’, J4´-3´ = 3.9 Hz); 7.85 (d, 1H, H3’); IR  cm-1: 3,263 (m, NH); 2,232 (w, CN); 1,694 (s, C=O); 
1,533 (s, NO2); 1,357 (s, NO2); 1,333 (s, N+O-); Anal. Calc. for C14H7N5O6: C:49.28%; H:2.07%; 
N:20.52%. Found: C: 48.88%; H: 2.24%; N: 20.70%. 
 
5-Nitrofuran-2-carboxylic acid (3-cyano-6-methyl-1,4-di-N-oxide-quinoxalin-2-yl)amide (26). Yield 
23.5 %; 1H-NMR  ppm: 8.41 (d, 1H, H8, J8-7 = 8.9 Hz); 8.31 (s, 1H, H5); 7.95 (d, 1H, H7); 7.89 (d, 
1H, H4’, J4’-3’ = 3.8 Hz); 7.84 (d, 1H, H3´); 2.61 (s, 3H, CH3); IR  cm-1: 3,250 (w, NH); 2,236 (w, 
CN); 1,701 (s, C=O); 1,527 (s, NO2); 1,355 (s, NO2); 1,332 (s, N+O-); Anal. Calc. for C15H9N5O6: C: 
50.71%; H: 2.55%; N: 19.71%. Found: C: 50.78%; H: 2.61%; N: 19.83%. 
5-Nitrofuran-2-carboxylic acid (3-cyano-6,7-dimethyl-1,4-di-N-oxide-quinoxalin-2-yl)amide (27). 
Yield 11.3 %; 1H-NMR  ppm: 8.31 (s, 1H, H8); 8.28 (s, 1H, H5); 7.91 (d, 1H, H4’, J4’-3’ = 3.9 Hz); 
7.85 (d, 1H, H3’); 2.54 (s, 3H, CH3); 2.53 (s, 3H, CH3); IR  cm-1: 3,173 (m, NH); 2,942 (w, CH3); 
2,232 (w, CN); 1,700 (s, C=O); 1,542 (s, NO2); 1,349 (s, NO2); 1,317 (s, N+O-); Anal. Calc. for 
C16H11N5O6: C: 52.04%; H: 3.00%; N: 18.96%. Found: C: 52.35%; H: 3.25%; N: 18.61%. 
5-Nitrofuran-2-carboxylic acid (3-cyano-6-methoxy-1,4-di-N-oxide-quinoxalin-2-yl)amide (28). Yield 
30.1 %; 1H-NMR  ppm: 8.45 (d, 1H, H8, J8-7 = 9.0 Hz); 7.90 (d, 1H, H4´, J4´-3´= 3.9 Hz); 7.85 (d, 1H, 
H3´); 7.79 (d, 1H, H5, J5-7=2.5Hz); 7.74 (dd, 1H, H7); 4.04 (s, 3H, OCH3); IR  cm-1: 3,129 (m, NH); 
2,239 (w, CN); 1,693 (s, C=O); 1,538 (s, NO2); 1,388 (s, NO2); 1,326 (s, N+O-); Anal. Calc. for 
C15H9N5O7: C: 48.53 %; H: 2.44 %; N: 18.86%. Found: C: 48.23%; H: 2.41%; N: 18.66%. 
5-Nitrofuran-2-carboxylic acid (6-chloro-3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)amide (29). Yield 
16.5 %; 1H-NMR  ppm: 8.49-8.45 (m, 2H, H8+H5); 8.13 (dd, 1H, H7, J7-8 = 9.2 Hz, J7-5=2.1 Hz); 7.87 
(d, 1H, H4’, J4´-3´= 3.8 Hz); 7.83 (d, 1H, H3’); 5.75 (s, 1H, NH); IR  cm-1: 3,273 (m, NH); 2,238 (w, 
CN); 1,711 (s, C=O); 1,537 (s, NO2); 1,351 (s, NO2); 1,327 (s, N+O-); 1,077 (m, Ar-Cl); Anal. Calc. 
for C14H6ClN5O6: C: 44.76 %; H: 1.61%; N: 18.64%. Found: C: 44.72%; H: 1.80%; N: 18.53%. 
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5-Nitrofuran-2-carboxylic acid (6,7-dichloro-3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)amide (30). 
Yield 12.4 %; 1H-NMR  ppm: 8.70 (s, 1H, H8); 8.66 (s, 1H, H5); 7.87 (d, 1H, H4’, J4’-3’ = 3.9 Hz); 
7.84 (d, 1H, H3’); IR  cm-1: 3,263 (m, NH); 2,244 (w, CN); 1,711 (s, C=O); 1,539 (s, NO2); 1,355 (s, 
NO2); 1,330 (s, N+O-); 1,073 (m, Ar-Cl); Anal. Calc. for C14H5Cl2N5O6: C: 41.00%; H: 1.23%; N: 
17.08%. Found: C: 41.15%; H: 1.30%; N: 17.25%. 
5-Nitrofuran-2-carboxylic acid (6-fluoro-3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)amide (31). Yield 
9.9 %; 1H-NMR  ppm: 8.58 (dd, 1H, H8, J8-7 = 9.4 Hz, J8-F  = 5.0 Hz); 8.30 (dd, 1H, H5, J5-F  = 8.7 Hz, 
J5-7  = 2.5 Hz); 8.06-8.01 (m, 1H, H7); 7.90 (d, 1H, H4’, J4’-3’  = 3.9 Hz); 7.84 (d, 1H, H3’); IR  cm-1: 
3,237 (m, NH); 2,238 (w, CN); 1,708 (s, C=O); 1,536 (s, NO2); 1,357 (s, NO2); 1,331 (s, N+O-); 
1,114 (m, Ar-F); Anal. Calc. for C14H6FN5O6: C: 46.81%; H: 1.68%; N: 19.50% Found: C: 46.53%; H: 
1.74%; N: 19.55%. 
5-Nitrofuran-2-carboxylic acid (6,7-difluoro-3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)amide (32). 
Yield 38.6 %; 1H-NMR  ppm: 8.63 (dd, 1H, H8, J8-F7 = 9.9 Hz, J8-F6 = 7.2 Hz); 8.58 (dd, 1H, H5, J5-F6 
= 9.9 Hz, J5-F7 = 7.3Hz); 7.89 (d, 1H, H4’, J4’-3’ = 3.9 Hz); 7.84 (d, 1H, H3’); 5.76 (s, 1H, NH); IR  cm-
1: 3,268 (m, NH); 2,244 (w, CN); 1,711 (s, C=O); 1,534 (s, NO2); 1,394 (s, NO2); 1,350 (s, N+O-); 
1,106 (m, Ar-F); Anal. Calc. for C14H5F2N5O6: C: 44.58%; H: 1.34%; N: 18.57%. Found: C: 44.04%; 
H: 1.34%; N: 18.33%. 
5-Nitrofuran-2-carboxylic acid (7-trifluoromethyl-3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)amide (33). 
Yield 39.8 %; 1H-NMR  ppm: 8.67 (s, 1H, H8); 8.54 (d, 1H, H5, J5-6 = 8.9 Hz); 8.37 (dd, 1H, H6, J6-8 = 
1.6 Hz); 7.84 (s, 2H, H4´+H3´); IR  cm-1: 3,275 (m, NH); 2,244 (w, CN); 1,707 (s, C=O); 1,536 (s, 
NO2); 1,391 (s, NO2); 1,350 (s, N+O-); 1,173 (m, Ar-CF3); Anal. Calc. for C15H6F3N5O6: C: 44.02%; 
H: 1.48%; N: 17.11%. Found: C: 44.08%; H: 1.47%; N: 16.71%. 
5-Nitrofuran-2-carboxylic acid (6-trifluoromethyl-3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)amide (34). 
Yield 51.8 %; 1H-NMR  ppm: 8.68 (s, 1H, H5); 8.66 (d, 1H, H8, J8-7=9.1Hz); 8.30 (d, 1H, H7); 7.89 
(d, 1H, H4’, J4´-3´=3.9Hz); 7.84 (d, 1H, H3’). IR  cm-1: 3277 (m, NH); 2238 (w, CN); 1709 (s, C=O); 
1538 (s, NO2); 1391 (s, NO2); 1350 (s, N+O-); 1173 (m, Ar-CF3). Calculated analysis for C15H6F3N5O6: 
C:44.02%; H:1.48%; N:17.11%. Found: C:44.26%; H:1.61%; N:16.43%. 
5-Nitrothiophene-2-carboxylic acid (3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)amide (35). Yield 36.2 
%; 1H-NMR  ppm: 8.49 (s, 1H, H8), 8.47 (s, 1H, H5), 8.26-8.23 (m, 2H, H4’+H3´) 8.11 (dd, 1H, H6, J6-
5 = 8.3 Hz, J6-7 = 7.4 Hz), 8.00 (dd, 1H, H7, J7-8 = 8.1 Hz); IR  cm-1: 3,278 (w, NH); 2,232 (w, CN); 
1,673 (s, C=O); 1,538 (s, NO2); 1,356 (m, NO2); 1,333 (s, N+O-); Anal. Calc. for C14H7N5O5S: C: 
47.06%;  H: 1.97%; N: 19.60%. Found: C: 47,16 %; H: 2.31%; N: 19.31%. 
5-Nitrothiophene-carboxylic acid (3-cyano-6-methyl-1,4-di-N-oxide-quinoxalin-2-yl)amide (36). Yield 
41.3 % 1H-NMR  ppm: 8.41 (d, 1H, H8, J8-7 = 8.8 Hz); 8.31 (s, 1H, H5); 8.25 (s, 2H, H3’+H4’); 7.96 
(dd, 1H, H7, J7-8 = 8.8 Hz, J7-5 = 1.7 Hz); 2.61 (s, 3H, CH3); IR  cm-1: 3,231 (w, NH); 2,238 (w, CN); 
1,677 (s, C=O); 1,528 (m, NO2); 1,348 (m, NO2); 1,325 (s, N+O-); Anal. Calc. for C15H9N5O5S: C: 
48.52%; H: 2.44%; N: 18.86%. Found: C: 48.26%; H: 2.48%; N: 19.05%.  
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5-Nitrothiophene-2-carboxylic acid (3-cyano-6,7-dimethyl-1,4-di-N-oxide-quinoxalin-2-yl)amide (37). 
Yield 8.6 %; 1H-NMR  ppm: 8.29 (s, 1H, H8); 8.28 (s, 1H, H5); 8.24 (s, 2H, H3´+H4´); 5.76 (s, 1H, 
NH); 2.54 (s, 3H, CH3); 2.52 (s, 3H, CH3). IR  cm-1: 3,244 (w, NH); 2,238 (w, CN); 1,676 (m, 
C=O); 1,528 (s, NO2); 1,372 (m, NO2); 1,332 (s, N+O-). Anal. Calc. for C16H11N5O5S: C: 49.87%; H: 
2.88%; N:18.17%. Found: C: 49.82%; H: 2.98%; N: 18.00%. 
5-Nitrothiophene-2-carboxylic acid (3-cyano-6-methoxy-1,4-di-N-oxide-quinoxalin-2-yl)amide (38). 
Yield 5.6 %; 1H-NMR  ppm: 8.43 (d, 1H, H8, J8-7 = 8.8 Hz); 8.22 (d, 1H, H4´, J4´-3´ = 4.0 Hz); 8.16 (d, 
1H, H3´); 7.77 (s, 1H, H5); 7.72 (d, 1H, H7); 4.03 (s, 3H, OCH3); IR  cm-1: 3,270 (w, NH); 2,238 (w, 
CN); 1,681 (w, C=O); 1,515 (s, NO2); 1,348 (m, NO2); 1,333 (s, N+O-); Anal. Calc. for C15H9N5O6S: 
C: 46.51 %; H: 2.34 %; N: 18.08%. Found: C: 46.64%; H: 2.52%; N: 18.28%. 
5-Nitrothiophene-2-carboxylic acid (6-chloro-3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)amide (39). 
Yield 36.7 %; 1H-NMR  ppm: 8.50 (d, 1H, H5, J5-7 = 2.2 Hz); 8.48 (d, 1H, H8, J8-7 = 9.2 Hz); 8.24 (d, 
1H, H4´, J4´-3´ = 4.4 Hz); 8.23 (d, 1H, H3´); 8.14 (dd, 1H, H7, J7-8 = 9.2 Hz, J7-5 = 2.2 Hz); IR  cm-1: 
3,275 (w, NH); 2,239 (w, CN); 1,677 (s, C=O); 1,519 (s, NO2); 1,357 (m, NO2); 1,323 (s, N+O-); 
1,090 (m, Ar-Cl); Anal. Calc. for C14H6ClN5O5S: C: 42.92 %; H: 1.54%; N: 17.88%. Found: C: 
43.01%; H: 1.71%; N: 18.02%. 
5-Nitrothiophene-2-carboxylic acid (6,7-dichloro-3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)amide (40). 
Yield 4.4 %; 1H-NMR  ppm: 8.66 (s, 1H, H8); 8.60 (s, 1H, H5); 8.19 (s, 1H, H4’); 8.05 (s, 1H, H3’); IR 
 cm-1: 3,256 (w, NH); 2,238 (w, CN); 1,675 (m, C=O); 1,505 (s, NO2); 1,354 (m, NO2); 1,330 (s, 
N+O-); Anal. Calc. for C14H5Cl2N5O5S: C: 39.46%; H: 1.18%; N: 16.43%. Found: C: 39.00%; H: 
1.35%; N: 16.07%. 
5-Nitrothiophene-2-carboxylic acid (6-fluoro-3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)amide (41). 
Yield 24.0 %; 1H-NMR  ppm: 8.60-8.56 (m, 1H, H8); 8.32-8.29 (m, 1H, H5); 8.25 (s, 2H, H4´+H3´); 
8.07-8.02 (m, 1H, H6); 5.76 (s, 1H, NH); IR  cm-1: 3,293 (m, NH); 2,238 (w, CN); 1,671 (s, C=O); 
1,514 (s, NO2); 1,349 (m, NO2); 1,332 (s, N+O-); 1,114 (m, Ar-F); Anal. Calc. for C14H6FN5O5S: C: 
44.81%; H: 1.61%; N: 18.66%. Found: C: 44.31%; H: 1.69%; N: 18.44%. 
5-Nitrothiophene-2-carboxylic acid (6,7-difluoro-3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)amide (42). 
Yield 33.4 %; 1H-NMR  ppm: 8.65-8.55 (m, 2H, H8+H5); 8.24 (d, 1H, H4´, J4´-3´ = 4.5 Hz); 8.23 (d, 
1H, H3´); IR  cm-1: 3,256 (w, NH); 2,232 (w, CN); 1,685 (s, C=O); 1,517 (s, NO2); 1,359 (s, NO2); 
1,341 (s, N+O-); Anal. Calc. for C14H5F2N5O5S: C: 42.76%; H: 1.28%; N: 17.81%. Found: C: 42.78%; 
H: 1.30%; N: 17.89%. 
5-Nitrothiophene-2-carboxylic acid (7-trifluoromethyl-3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)amide 
(43). Yield 51.8 %; 1H-NMR  ppm: 8.65 (d, 1H, H5, J5-6 = 8.8 Hz); 8.65 (s, 1H, H8); 8.27 (dd, 1H, H6, 
J6-8 = 1.5Hz); 8.23 (d, 1H, H4’, J4´-3´ = 4.4 Hz); 8.18 (d, 1H, H3’); IR  cm-1: 3,244 (w, NH); 2,238 (w, 
CN); 1,672 (s, C=O); 1,506 (s, NO2); 1,399 (s, NO2); 1,338 (s, N+O-); 1,130 (m, Ar-CF3); Anal. Calc. 
for C15H6F3N5O5S: C: 42.36%; H: 1.42%; N: 16.47%. Found: C: 42.58%; H: 1.60%; N: 16.49%. 
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5-Nitrothiophene-2-carboxylic acid (6-trifluoromethyl-3-cyano-1,4-di-N-oxide-quinoxalin-2-yl)amide 
(44). Yield 57.9 %; 1H-NMR  ppm: 8.64 (s, 1H, H5); 8.47 (d, 1H, H8, J8-7 = 8.9 Hz); 8.35 (d, 1H, H7); 
8.20 (d, 1H, H4’, J4´-3´ = 4.3 Hz); 8.08 (d, 1H, H3’); IR  cm-1: 3,247 (w, NH); 2,238 (w, CN); 1,675 (s, 
C=O); 1,520 (s, NO2); 1,399 (m, NO2); 1,333 (s, N+O-); 1,139 (m, Ar-CF3); Anal. Calc. for 
C15H6F3N5O5S: C: 42.36%; H: 1.42%; N: 16.47%. Found: C: 42.62%; H: 1.72%; N: 16.57%. 
In vitro evaluation of antituberculosis activity 
In vitro evaluation of the antituberculosis activity was carried out at the GWL Hansen’s Disease 
Center within the Tuberculosis Antimicrobial Acquisition & Coordinating Facility (TAACF) screening 
program for the discovery of novel drugs for the treatment of tuberculosis. The Southern Research 
Institute coordinates the overall program under the direction of the U.S. National Institute of Allergy 
and Infectious Disease (NIAID). The purpose of the screening program is to provide a resource 
whereby new experimental compounds can be tested for their capability to inhibit the growth of 
virulent M. tuberculosis [26]. 
Determination of growth inhibition percentage via MABA: The initial screen is conducted against 
Mycobacterium tuberculosis H37Rv (ATCC 27294) in BACTEC 12B medium using the Microplate 
Alamar Blue Assay (MABA) [27]. The fluorescence changes due to the reduction of Alamar blue dye 
during the growth of Mycobacterium were monitored by the BACTEC 460-radiometric system. 
Compounds effecting <90% inhibition in the primary screen (MIC >6.25 g/mL) were not further 
evaluated.  
Determination of minimum inhibitory concentration (MIC) via MABA: Compounds demonstrating at 
least 90% inhibition in the primary screen were re-tested against M. tuberculosis H37Rv at lower 
concentrations in order to determine the actual minimum inhibitory concentration (MIC) in the 
MABA. The MIC was defined as the lowest concentration effecting a reduction in fluorescence of 
90% relative to controls. RIF was used as the reference compound (RIF MIC = 0.015–0.125 g/mL). 
In vitro evaluation of trypanocidal activity 
Trypanosoma cruzi epimastigotes (Tulahuen 2 strain) were grown at 28 ºC in an axenic medium 
(BHI-Tryptose) as previously described [28-30], supplemented with 5% fetal bovine serum (FBS). 
Cells from a 10-day-old culture (stationary phase) were inoculated into 50 mL of fresh culture medium 
in order to give an initial concentration of 1  106 cells/mL. Cell growth was followed by measuring 
the absorbance of the culture at 600 nm daily. Before inoculation, the medium was supplemented with 
the indicated amount of the drug from a stock solution in DMSO. The final concentration of DMSO in 
the culture medium never exceeded 0.4%, and the control was run in the presence of 0.4% DMSO and 
in the absence of any drug. No effect on epimastigote growth was observed by the presence of up to 
1% DMSO in the culture medium. The percentage of growth inhibition (PGI) was calculated as 
follows: PGI (%) = {1 - [(Ap - A0p)/(Ac - A0c)]}  100, where Ap = A600 of the culture containing the 
drug at day 5; A0p = A600 of the culture containing the drug just after addition of the inocula (day 
0);Ac = A600 of the culture in the absence of the drug (control) at day 5; A0c = A600 in the absence of 
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the drug at day 0. In order to determine IC50 values, 50% inhibitory concentrations, parasite growth 
was observed in the absence (control) and presence of increasing concentrations of the corresponding 
drug. At day 5, the absorbance of the culture was measured and related to the control. The IC50 value 
was considered to be the concentration of drug needed for reducing the absorbance ratio to 50%. 
Conclusions 
New structural modifications on the QDO skeleton were performed, and promising biological 
results against M. tuberculosis and T. cruzi were obtained. The biological evaluation showed a broad 
range of activities, thereby showing new structural hits for future chemical pharmacomodulations of 
QDO for the development of new drugs against tuberculosis and Chagas disease. 
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